Skip to main content

Agrochemicals shares in focus; Monsanto India surges over 30% in two days


Monsanto India, Atul, Sharda Cropchem, Rallis India and Bayer CropScience were up 3%-18% on the BSE.
Shares of the companies engaged in agrochemicals business have rallied by up 18% on the back of heavy volumes on the Bombay Stock Exchange (BSE) in intra-day trade.
Monsanto India, Atul, Sharda Cropchem, Excel Crop Care, Rallis India, Bayer CropScience, UPL, PI Industries, Dhanuka Agritech and Insecticides (India) were up in the range of 1%-18% on the BSE.
Monsanto India has soared 18% to Rs 2,423, extending its previous day’s rally on the BSE, on back of heavy volumes. In past two trading sessions, the stock zoomed 33% from Rs 1,818 on May 10.
The trading volumes on the counter jumped an over 10-fold with a combined 815,269 shares changed hands on the NSE and BSE till 10:52 am.
Monsanto India is schedule to announce its January-March 2016 quarter (Q4FY16) results on May 30, 2016.
Motilal Oswal Securities expects Q4FY16 Ebitda (earnings before interest, tax, depreciation, and amortisation) margins at 5% and Ebitda at Rs 3.4 crore as against a negative Ebitda of Rs 10.40 crore in Q4FY15.
Atul hit a 52-week high of Rs 2,035, up 3%; extending its 8% gain in past eight trading sessions post Q4 results.
A diversified chemical company from the Lalbhai Group, Atul has reported 40% year on year (YoY) growth in net profit at Rs 63 crore for the quarter ended March 31, 2016 (Q4FY16).
The company’s crop protection division manufactures fungicides, herbicides and weedicides, posted robust growth in FY16.
“Management highlighted that FY16 was relatively better than FY15 for its portfolio of products. With expectations of better monsoons in India, management’s outlook for FY17 is promising,” IIFL Institutional Equities said in a results update.
Sharda Cropchem has rallied 6% to Rs 299 on the BSE in intra-day trade. Emkay Research believes the company is well poised to record healthy growth in Q4 driven by commencement of sowing season in key markets of Europe and NAFTA where it has a strong presence. Change in geographic mix and richer product mix led by new registrations coupled with benign RM cost should aid margin expansion.
Bayer CropScience too moved higher to its 52-week high of Rs 4,155, up 5% on the BSE ahead of board meeting on May 13 to consider Q4 FY16 results.

Comments

Post a Comment

Popular posts from this blog

Wizard of Dalal Street: Govind Parikh's investment mantra

Wizard of Dalal Street: Govind Parikh's investment mantra Govind Parikh of Govind Parikh Securities says selling right is more important than correct buying. He says it is necessary to keep a lot of cash. "We keep an average 10 percent cash in our portfolio," he says I like to buy things in a bad market. Additionally, don't look current cash flow, concentrate on future cash flows — that is what  I look at," says Govind Parikh of Govind Parikh Securities. He advises investors to buy good quality stocks when the market crashes. While sharing his investment philosophy with ace investor Ramesh Damani, on the Wizards of Dalal Street, Parikh says management integrity is very important when deciding which stock to bet on. He tells investors not to buy stocks impulsively. According to him, selling right is more important than correct buying. He says it is necessary to keep a lot of cash. "We keep an average 10 percent cash in our portfolio," he says. He al...
2 comments
Read more

Bank Nifty

Bank Nifty Bank Nifty is a Sell at Current Levels with a Stop Loss of 12,750 Once Below 12,400 the next major Support shall be only 12,000 Levels so a person can go short is bearish or buy putt if moderately bearish . 
7 comments
Read more

Budget 2018: Mega health plan to cost Rs 1 lakh crore

The mega healthcare plan for the poor, as announced in the Budget, will cost about Rs 1,00,000 crore annually and curtail states' autonomy to design their own policies in the sector, says a research paper, authored by a professor at economic think tank NIPFP. The paper's estimate is 10 times higher than the one made last week by Niti Aayog adviser Alok Kumar, who had said that the National Health Protection Scheme (NHPS) will cost around Rs 10,000-12,000 crore annually. National Institute of Public Finance and Policy (NIPFP) Assistant Professor Mita Choudhury said in the paper -- 'The National Health Protection Scheme in the Union  Budget 2018 : Is it in the Right Direction?' -- that resource requirements for implementing NHPS are likely to be very high. Not only would such a scheme impose a heavy burden on both the Union and the states' exchequers, it will also curtail states' autonomy to design their own policies in a sector that is constitutionally ma...
Post a Comment
Read more